Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma.

Persons

Brian Nahed

Venue / Journal

Neurooncol Adv

Date

Wed, 01/01/2020 - 12:00

Additional Journal Information

2(1):vdaa031

Authors

Vaios EJ, Winter SF, Muzikansky A, Nahed BV, Dietrich J.

Pubmed URL

http://www.ncbi.nlm.nih.gov/pubmed/32642690